Skip to main content
. 2021 Feb 16;8(2):241–251. doi: 10.1007/s40801-021-00233-y

Table 2.

Characteristics and distribution of adverse events (AEs)

Certain Probable Possible Unlikely
Causality, n 24 31 10 2
Local Systemic
Type of AE, n 57 24
Immediate Delayed
Time of onset, n 56 12
Mild Moderate Severe
Severity, n 58 10 0
Initiation Maintenance
Treatment phase, n 29 39
None Dose reduction Temporary suspension Added premedication Restart with premedication
Action taken, n 48 6 4 5 5